Categorical prevalence and severity of hyperprolactinaemia in two UK cohorts of patients with severe mental illness during treatment with antipsychotics
Authors:
- 1 March 2008
- journal article
- research article
- Published by SAGE Publications in Journal of Psychopharmacology
- Vol. 22 (2_suppl) , 56-62
Abstract
Hyperprolactinaemia may be associated with hidden longer-term consequences, such as osteoporosis, bone fractures, pituitary tumours and breast cancer. Prolactin data from clinical trials is not always reported in a categorical manner and does not always allow the risk of hyperprolactinaemia to be evaluated for specific patient cohorts. Patients participating in a physical health management programme in the UK for severe mental illness patients — the Well-being Support Programme — had prolactin measurements made regardless of symptoms. Prolactin data from the complete cohort of 178 patients receiving antipsychotics in Leeds and London are reported. Hyperprolactinaemia was measured in 33.1% but more commonly in females than males (47.3% and 17.6%) and was associated with all antipsychotics except clozapine. The highest prevalence rates were found in amisulpride (n=20) 89%, risperidone long-acting intramuscular injection (LAIM) 67% (n=6) and risperidone (n=30) 55% used as antipsychotic monotherapy. Clinically Significant hyperprolactinaemia (>1000 mIU/L ~47 ng/ml) was measured in 15.8% of patients, predominantly in females. Levels >2000 mIU/L ~95 ng/ml in 6.2% of the complete cohort. Clinicians may wish to add prolactin measurement to the routine laboratory parameters currently measured for some antipsychotics and should be advised of the potential longer-term consequences of hidden hyperprolactinaemia.Keywords
This publication has 36 references indexed in Scilit:
- Adverse effects of prolactin in rodents and humans: breast and prostate cancerJournal of Psychopharmacology, 2008
- A review of the association between antipsychotic use and hyperprolactinaemiaJournal of Psychopharmacology, 2008
- Current guidelines and their recommendations for prolactin monitoring in psychosisJournal of Psychopharmacology, 2008
- Prevalence of hyperprolactinaemia in a naturalistic cohort of schizophrenia and bipolar outpatients during treatment with typical and atypical antipsychoticsJournal of Psychopharmacology, 2007
- Risk of hip fracture in patients with a history of schizophreniaThe British Journal of Psychiatry, 2007
- Osteoporosis in Patients With SchizophreniaAmerican Journal of Psychiatry, 2005
- Antipsychotic-Induced HyperprolactinaemiaDrugs, 2004
- Risperidone, but Not Olanzapine, Decreases Bone Mineral Density in Female Premenopausal Schizophrenia PatientsThe Journal of Clinical Psychiatry, 2003
- Elevated prolactin levels in patients with schizophrenia: mechanisms and related adverse effectsPsychoneuroendocrinology, 2003
- The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophreniaClinical Therapeutics, 2000